Loading
A lung cancer study that tracked ALK fusions in blood using both RNA and DNA, finding some only in the RNA.
ALK rearrangements were detected in 15 of 28 patients at baseline, eight in both circulating tumour DNA and RNA; in two patients they were found before local consolidative therapy only in the RNA and cleared afterwards. The authors conclude that including circulating tumour RNA increased detection.
Same-draw RNA and DNA together catch fusions one alone misses.
Shares Read tumour RNA and tumour DNA from the same blood draw to find and type residual cancer, Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).
Shares Read tumour RNA and tumour DNA from the same blood draw to find and type residual cancer, Liquid RNA biopsy (cell-free, vesicle and platelet RNA).
Shares Read tumour RNA and tumour DNA from the same blood draw to find and type residual cancer, Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Liquid biopsy (ctDNA).
Shares Read tumour RNA and tumour DNA from the same blood draw to find and type residual cancer, Liquid RNA biopsy (cell-free, vesicle and platelet RNA).
Shares Read tumour RNA and tumour DNA from the same blood draw to find and type residual cancer, Liquid RNA biopsy (cell-free, vesicle and platelet RNA).
Shares Read tumour RNA and tumour DNA from the same blood draw to find and type residual cancer, Liquid RNA biopsy (cell-free, vesicle and platelet RNA).
Shares Read tumour RNA and tumour DNA from the same blood draw to find and type residual cancer, Liquid RNA biopsy (cell-free, vesicle and platelet RNA).
Shares Read tumour RNA and tumour DNA from the same blood draw to find and type residual cancer, Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/